OpenEvidence, the “ChatGPT for Doctors,” Raises $210 Million
The platform that helps doctors access evidence-based answers says it now serves over 40% of U.S. physicians and plans plans to expand its tools and partnerships.
OpenEvidence, a U.S.-based artificial intelligence company focused on clinical decision support, has raised $210 million in a Series B funding round, bringing its reported valuation to $3.5 billion. The platform is designed to help physicians navigate the overwhelming volume of medical research and guidelines by using AI to deliver evidence-based answers at the point of care. As the medical field struggles with information overload and growing physician burnout, tools like OpenEvidence are being increasingly viewed as part of the solution to modernize clinical practice.
According to the company, OpenEvidence is now used by more than 40% of practicing physicians in the United States. It claims that its platform handles approximately 8.5 million patient consultations per month, with more than 65,000 new U.S. clinicians joining monthly. The company also states that its total user base spans over 10,000 hospitals and medical centers.
The Series B round was co-led by Google Ventures (GV) and Kleiner Perkins, with continued participation from existing investor Sequoia Capital, and additional backing from Coatue, Conviction, and Thrive Capital. This brings OpenEvidence’s total funding to more than $300 million since its launch in 2021.
The platform includes two main tools: a search engine that provides physicians with rapid, cited clinical answers in 5 to 10 seconds, and a newly launched feature called DeepConsult. According to the company, DeepConsult is an AI agent capable of reviewing hundreds of studies autonomously, producing synthesized reports to support complex medical decisions. The tool is available at no cost to verified U.S. physicians and is compliant with HIPAA regulations, the company says.
OpenEvidence also highlights partnerships with several leading medical publishers, including the New England Journal of Medicine, the American Medical Association, and the JAMA Network. These agreements reportedly allow the platform to include high-quality clinical content in its database, further supporting its aim of delivering trustworthy, evidence-backed answers to clinicians.
Commenting on the investment, GV General Partner Sangeen Zeb said the volume of medical information physicians must process has become “unmanageable,” and tools like OpenEvidence could help surface relevant insights more effectively. Kleiner Perkins’ Mamoon Hamid added that the platform’s traction among physicians is a strong indicator of trust and utility.
The company plans to use the new funding to grow its user base, expand its partnerships, and enhance its AI capabilities. As healthcare systems face ongoing staffing pressures and increasing demand, OpenEvidence positions itself as a key player in the evolving intersection of AI and clinical practice.